1. Home
  2. BTAI vs YQ Comparison

BTAI vs YQ Comparison

Compare BTAI & YQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo BioXcel Therapeutics Inc.

BTAI

BioXcel Therapeutics Inc.

HOLD

Current Price

$0.07

Market Cap

24.8M

Sector

Health Care

ML Signal

HOLD

YQ

17 Education & Technology Group Inc.

N/A

Current Price

$3.35

Market Cap

22.2M

Sector

Real Estate

ML Signal

N/A

Company Overview

Basic Information
Metric
BTAI
YQ
Founded
2017
2012
Country
United States
China
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Other Consumer Services
Sector
Health Care
Real Estate
Exchange
Nasdaq
Nasdaq
Market Cap
24.8M
22.2M
IPO Year
2018
2020

Fundamental Metrics

Financial Performance
Metric
BTAI
YQ
Price
$0.07
$3.35
Analyst Decision
Strong Buy
Analyst Count
4
0
Target Price
$23.00
N/A
AVG Volume (30 Days)
11.2M
69.8K
Earning Date
05-08-2026
06-09-2026
Dividend Yield
N/A
N/A
EPS Growth
75.63
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$197.82
N/A
Revenue Next Year
$910.15
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.07
$1.68
52 Week High
$3.19
$6.45

Technical Indicators

Market Signals
Indicator
BTAI
YQ
Relative Strength Index (RSI) 19.82 59.07
Support Level N/A $3.28
Resistance Level $1.22 $3.68
Average True Range (ATR) 0.06 0.43
MACD -0.07 0.13
Stochastic Oscillator 0.57 57.65

Price Performance

Historical Comparison
BTAI
YQ

About BTAI BioXcel Therapeutics Inc.

BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are-BXCL501, being evaluated as a potential treatment for agitation associated with multiple neurological disorders and BXCL701, an investigational oral innate immune activator for the treatment of aggressive forms of prostate cancer and other solid and liquid tumors. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.

About YQ 17 Education & Technology Group Inc.

17 Education & Technology Group Inc is engaged in providing education and education technology services in the People's Republic of China (PRC) with a focus on the Teaching and Learning SaaS offerings. It offers smart, in-school, teaching and learning SaaS offerings assist students, teachers, schoolmasters and educational authorities across China. It also offer other educational products and services that complement students' in-school learning. Geographically group operates in China.

Share on Social Networks: